Compare · ILMN vs TWST
ILMN vs TWST
Side-by-side comparison of Illumina Inc. (ILMN) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ILMN focuses on Medical Specialities, while TWST focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- ILMN is the larger of the two at $30.95B, about 3.3x TWST ($9.44B).
- Over the past year, ILMN is up 101.9% and TWST is up 415.7% - TWST leads by 313.9 points.
- TWST has been more active in the news (26 items in the past 4 weeks vs 13 for ILMN).
- ILMN has more recent analyst coverage (25 ratings vs 15 for TWST).
- Company
- Illumina Inc.
- Twist Bioscience Corporation
- Price
- $205.11+8.99%
- $142.29+22.57%
- Market cap
- $30.95B
- $9.44B
- 1M return
- +6.48%
- +48.47%
- 1Y return
- +101.86%
- +415.73%
- Industry
- Medical Specialities
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2000
- 2018
- News (4w)
- 13
- 26
- Recent ratings
- 25
- 15
Illumina Inc.
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest ILMN
- SEC Form 8-K filed by Illumina Inc.
- Illumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- SEC Form 8-K filed by Illumina Inc.
- SEC Form 3 filed by new insider Coletti Julie Ann
- SEC Form FWP filed by Illumina Inc.
- Chief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)
- Illumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Director Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)
- Chief Legal Officer Davies Scott M sold $123,000 worth of shares (615 units at $200.00), decreasing direct ownership by 3% to 20,338 units (SEC Form 4)
- SEC Form 10-Q filed by Illumina Inc.
Latest TWST
- Twist Bioscience Corporation filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Twist Bioscience Corporation
- SEC Form SCHEDULE 13G filed by Twist Bioscience Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation
- Chief Executive Officer Leproust Emily M. exercised 113,318 shares at a strike of $26.66 and sold $14,183,051 worth of shares (113,318 units at $125.16) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Twist Bioscience Corporation
- Director Chess Robert sold $2,042,261 worth of shares (18,417 units at $110.89) as part of a pre-agreed trading plan and exercised 18,417 shares at a strike of $11.89 (SEC Form 4)
- Officer Cho Dennis sold $1,558,999 worth of shares (14,205 units at $109.75) as part of a pre-agreed trading plan, decreasing direct ownership by 14% to 89,866 units (SEC Form 4)
- SEC Form 144 filed by Twist Bioscience Corporation